Welcome to NDF Research
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog
PCT patent applications related to the Life Sciences sector in Australia and New Zealand and published in 2017
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (31 December 2017)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.

Australian applications

Here are the 165 PCT patent applications relevant to Australia's Life Sciences sector that published in 2017, for a publication rate of 3.2 applications per week:​
  • WO/2017/221158, Anti-parasitic compositions and methods, University of Canberra, 28 December 2017
  • WO/2017/220369, Antibodies against MAC-1, Baker IDI Heart and Diabetes Institute and Albert-Ludwigs-Universität Freiburg, 28 December 2017
  • WO/2017/219087, New thiosemicarbazone compounds and analogues thereof, University of Sydney, 28 December 2017
  • WO/2017/219086, Anti-ageing compounds, University of Sydney, 28 December 2017
  • WO/2017/219083, Activators of HIV latency, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, 28 December 2017
  • WO/2017/219081, Spider venom peptides and methods of use for modulating sodium channels, University of Queensland, 28 December 2017
  • WO/2017/219080, Treatment for myopia, University of Newcastle, 28 December 2017
  • WO/2017/219078, Allosteric regulation of haemostatic activity, University of Sydney, 28 December 2017
  • WO/2017/214683, Methods and compositions for the treatment or prophylaxis of an ectoparasitic infestation, Gretals Australia Pty Ltd, 21 December 2017
  • WO/2017/214681, Agents and methods for the diagnosis and treatment of diseases associated with extracellular matrix turnover, Baker IDI Heart and Diabetes Institute, 21 December 2017
  • WO/2017/214680, Adamantane compounds, University of Sydney, 21 December 2017
  • WO/2017/210749, Methods and products for treating autoimmune diseases, University of Adelaide, 14 December 2017
  • WO/2017/210735, Methods of treating neuroblastoma and reagents therefor, Garvan Institute of Medical Research, 14 December 2017
  • WO/2017/210726, Peptides for hair growth, Clinical Stem Cells Pty Ltd, 14 December 2017
  • WO/2017/205939, Vitamin D formulations and therapeutic uses thereof, Indigo Ridge Pty Ltd, 7 December 2017
  • WO/2017/205901, Hydrophilic polymer conjugate with multiple antiviral agents for treating a viral infection, Commonwealth Scientific and Industrial Research Organisation, 7 December 2017
  • WO/2017/205895, Skin care formulation, Embryogenesis Pty Ltd, 7 December 2017
  • WO/2017/203397, Inner ear plug, Cochlear Ltd, 30 November 2017
  • WO/2017/203368, Methods of treating autoimmune disease using allogeneic T cells, QIMR Berghofer Medical Research Institute, 30 November 2017
  • WO/2017/203362, Immune checkpoint inhibitors and cytotoxic T cells for the treatment of cancer, QIMR Berghofer Medical Research Institute, 30 November 2017
  • WO/2017/201585, Modulators of DUX4 for regulation of muscle function, Genea Biocells, 30 November 2017
  • WO/2017/201581, Non-toxic iron chelators with neuroprotective potential, University of Sydney, 30 November 2017
  • WO/2017/201579, Arthrogenic alphavirus vaccine, Griffith University, 30 November 2017
  • WO/2017/201573, A method of classification and treatment, Peter MacCallum Cancer Institute, 30 November 2017
  • WO/2017/201563, Treatment of alphavirus-induced inflammation, Griffith University, 30 November 2017
  • WO/2017/197463, Treatment of pain, Monash University and Queens University at Kingston (Canada), 23 November 2017
  • WO/2017/197453, Microencapsulated omega-3 polyunsaturated fatty acid glyceride compositions and processes for preparing the same, Deakin University, 23 November 2017
  • WO/2017/194912, Treatment of complement-mediated disorders, University of Cambridge (UK) and Sydney Children's Hospital Network, 16 November 2017
  • WO/2017/193169, Protection of plant extracts and compounds from degradation, Medlab Clinical Ltd, 16 November 2017
  • WO/2017/193161, Agent delivery system, WRS Therapeutics Pty Ltd, 16 November 2017
  • WO/2017/192699, Adeno-Associated Virus polynucleotides, polypeptides and virions, Children's Medical Research Institute, Sydney Children's Hospital Network and US Department of Health and Human Services, 9 November 2017
  • WO/2017/190197, Reagents for treatment of Hepatitis B Virus (HBV) infection and use thereof, Benitec Biopharma Ltd, 9 November 2017
  • WO/2017/190193, Method of prophylaxis of Zika virus infection, Starpharma Ltd, 9 November 2017
  • WO/2017/190183, Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith, T & A Pharma Pty Ltd, 9 November 2017
  • WO/2017/185142, Method for preventing and/or treating atrial fibrillation, University of Adelaide, 2 November 2017
  • WO/2017/185123, Veterinary composition, Alan Thompson, 2 November 2017
  • WO/2017/181245, Method of treating inflammation and promoting wound healing, Sang Pacific Enterprises Pty Ltd, 26 October 2017
  • WO/2017/181243, Method of treating or preventing liver conditions, CSL Ltd and B-Creative Sweden AB, 26 October 2017
  • WO/2017/181242, Chemotherapy improvements, Noxopharm, 26 October 2017
  • WO/2017/177283, Methods of manufacturing nutritional formulations, Clover Corporation Ltd, 19 October 2017
  • WO/2017/177277, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, Benitec Biopharma Ltd, 19 October 2017
  • WO/2017/177270, Composition of proenzymes for cancer treatment, Propanc Biopharma, 19 October 2017
  • WO/2017/177265, Injectable composition for delivery of a biologically active agent, Capsular Technologies Pty Ltd, 19 October 2017
  • WO/2017/177262, Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier, University of Canberra, 19 October 2017
  • WO/2017/177261, Liposomal preparation and methods of treatment, Habi Pharma Pty Ltd, 19 October 2017
  • WO/2017/176403, Method and composition for dag mitigation on hair, Empire Technology Development LLC, 12 October 2017
  • WO/2017/173498, Isoflavonoid composition with improved pharmacokinetics, Noxopharm, 12 October 2017
  • WO/2017/173497, Targeted drug delivery, Noxopharm, 12 October 2017
  • WO/2017/173496, Radiotherapy improvements, Noxopharm, 12 October 2017
  • WO/2017/173494, Method of treating atherosclerosis, CSL Ltd, 12 October 2017
  • WO/2017/173487, Nanofibrous mat containing ceramic particles with releasable dopant, SG Ventures Pty Ltd and Nanopharma a.s. (Czechia)
  • WO/2017/173478, Acoustic wave mediated non-invasive drug delivery, Mupharma Pty Ltd, 12 October 2017
  • WO/2017/173474, Improvements in cancer treatment, Noxopharm, 12 October 2017
  • WO/2017/165908, Method of inhibiting high fat diet-related conditions, South Australian Health and Medical Research Institute and Ocean University of China (China), 5 October 2017
  • WO/2017/161414, Administration of an anti- LGR5 monoclonal antibody, Bionomics Ltd, 28 September 2017
  • WO/2017/161408, Dental adhesive compositions, SDI Ltd, 28 September 2017
  • WO/2017/161402, Formulation and method for the prevention and/or treatment of hangover symptoms, Phoenix Pharmaceuticals Australia Pty Ltd, 28 September 2017
  • WO/2017/160587, Neutralizing monoclonal antibodies to Il-25 and uses thereof, Abeome Corporation (US) with Nathan Bartlett and others
  • WO/2017/156591, Osteoarthritis miRNAs, Murdoch Childrens Research Institute and University of Sydney, 21 September 2017
  • WO/2017/156580, Colony forming medium and use thereof, Cynata Therapeutics, 21 September 2017
  • WO/2017/153521, Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
  • WO/2017/153520, Benzopiperidine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 4 September 2017
  • WO/2017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
  • 017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
  • WO/2017/153518, PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
  • WO/2017/153515, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
  • WO/2017/153513, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
  • WO/2017/152237, Novel analogues of Desferrioxamine B (DFOB), University of Sydney, 14 September 2017
  • WO/2017/147654, Use of phosphorylated tau and p38gamma to treat a neurological condition, University of New South Wales, 8 September 2017
  • WO/2017/147653, Methods of treating bone diseases, disorders and/or injuries and reagents therefor, Cellmid Ltd, 8 September 2017
  • WO/2017/147649, Methods of treatment, Magellan Stem Cells Pty Ltd, 8 September 2017
  • WO/2017/143406, Multi-specific molecules, Imunexus Pty Ltd, 31 August 2017
  • WO/2017/143397, Inhibitors of β-arrestin-neurokinin 1 receptor interactions for the treatment of pain, Monash University, 31 August 2017
  • WO/2017/142825, N3-substituted iminopyrimidinones as antimalarial agents, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
  • WO/2017/142821, Compounds for the treatment of malaria, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
  • WO/2017/139854, Compositions and methods for the treatment of sinus disease and disorders, ENT Technologies Pty Ltd, 24 August 2017
  • WO/2017/139849, Anti-virus agent and method for treatment of viral infection, Recce Ltd, 24 August 2017
  • WO/2017/139846, Formulation and method of use, ATP Institute Pty Ltd, 24 August 2017
  • WO/2017/139845, Novel alpha conotoxin peptides, University of Queensland, 24 August 2017
  • WO/2017/139290, Tralokinumab delivery device, Medimmune (US) and Unilife, 17 August 2017
  • WO/2017/136871, Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
  • WO/2017/136870, Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
  • WO/2017/132728, Proteinaceous compounds and uses therefor, University of Canberra, 10 August 2017
  • WO/2017/127892, Cancer treatment, Propanc Biopharma, 3 August 2017
  • WO/2017/124156, Compositions that brighten skin, provide sun protection, and permit Vitamin D production, Ernest Armstong, 27 July 2017
  • WO/2017/124147, Novel biomolecule conjugates and uses therefor, University of Western Australia and Sanford Burnham Prebys Medical Discovery Institute (US), 27 July 2017
  • WO/2017/117631, Mutated truncated von Willebrand factor, CSL Ltd, 13 July 2017
  • WO/2017/117630, Mutated von Willebrand factor, CSL Ltd, 13 July 2017
  • WO/2017/117627, Drug release device and use, Jurox Pty Ltd, 13 July 2017
  • WO/2017/112792, Tripartite modulators of endosomal G Protein-Coupled Receptors, Takeda Pharmaceutical Company (Japan) with two Monash University scientists, among others, 29 June 2017
  • WO/2017/106930, Compounds, Commonwealth Scientific and Industrial Research Organisation, 29 June 2017
  • WO/2017/106926, Nucleic acid oligomers and uses therefor, Queensland University of Technology, 29 June 2017
  • WO/2017/106899, Therapeutic methods using erythrocytes, Sangui Bio Pty Ltd, 29 June 2017
  • WO/2017/100863, Injectable composition and a method of treatment of the physical addiction, Verita Research Pte Ltd, 22 June 2017
  • WO/2017/100861, Inhibition of cytokine-induced SH2 protein in NK cells, Walter and Eliza Hall Institute of Medical Research, 22 June 2017
  • WO/2017/100860, Exfoliant bar, DPP Pharmaceuticals Pty Ltd, 22 June 2017
  • WO/2017/100858, Polymer composite for controlled release of an agent, Commonwealth Scientific and Industrial Research Organisation, 22 June 2017
  • WO/2017/100849, 6-oxopurine phosphoribosyl transferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry (Czechia), 22 June 2017
  • WO/2017/100825, A pharmaceutical composition and uses therefor, Robert Gilligan and Wayne Daley, 22 June 2017
  • WO/2017/100819, Modular syntheses of discoipyrrole type alkaloids and analogues, Australian National University, 22 June 2017
  • WO/2017/096432, Immunomodulating composition for treatment, Admedus, 15 June 2017
  • WO/2017/096431, Proteinaceous molecules and methods of use, University of Queensland, Florey Institute of Neuroscience and Mental Health, Johns Hopkins University (US) and the University of California (US), 15 June 2017
  • WO/2017/096430, Hydroxamic acid-based compounds, University of Sydney, 15 June 2017
  • WO/2017/096427, Pharmaceutical formulation, Phosphagenics Ltd, 15 June 2017
  • WO/2017/096426, Methods and compositions for treating gastric ulcers, Luoda Pharma Pty Ltd, 15 June 2017
  • WO/2017/093807, Methods of treating or alleviating mental disorders and associated symptoms, Florey Institute of Neuroscience and Mental Health and Deakin University, 8 June 2017
  • WO/2017/091866, Regulation of cytokine production, Commonwealth Scientific and Industrial Research Organisation, 8 June 2017
  • WO/2017/091850, Novel anti-angiogenic fusion polypeptides, Pieris Pharmaceuticals, 8 June 2017
  • WO/2017/088031, Photostable compounds, absorbing compounds and uses thereof, Commonwealth Scientific and Industrial Research Organisation, 1 June 2017
  • WO/2017/088028, CD131 binding proteins and uses thereof, CSL Ltd, 1 June 2017
  • WO/2017/088027, Inhibin analogs, Hudson Institute of Medical Research, 1 June 2017
  • WO/2017/088018, Production of viruses in cell culture, Commonwealth Scientific and Industrial Research Organisation and University of Georgia (US), 1 June 2017
  • WO/2017/088012, Genetically modified cells and uses thereof, Cartherics Pty Ltd, 1 June 2017
  • WO/2017/083938, Method of controlled competitive exchange, Anteo Diagnostics Ltd, 26 May 2017
  • WO/2017/083931, A non-surgical vulvovaginal rejuvenation technique and an injecting device therefor, Abbas Al-Taiff, 26 May 2017
  • WO/2017/083925, Compounds and methods for treating metabolic disorders, Garvan Institute of Medical Research, 26 May 2017
  • WO/2017/083914, Compounds for medicinal applications, Australian Biomedical Co. Pty Ltd, 26 May 2017
  • WO/2017/079802, Proenzyme composition, Propanc Biopharma, 18 May 2017
  • WO/2017/078928, FXR agonists and methods for making and using, Salk Institute for Biological Studies (US) and University of Sydney, 11 May 2017
  • WO/2017/078927, Analogs of fexaramine and methods of making and using, Salk Institute for Biological Studies (US) and University of Sydney, 11 May 2017
  • WO/2017/075672, Method and product for testing response to oral glucose load, INR Enterprises Pty Ltd, 11 May 2017
  • WO/2017/075670, Mobilizing leukemia cells, Children's Hospital Los Angeles (US) and Antisense Therapeutics, 11 May 2017
  • WO/2017/075661, Methods and compositions for treating CNS injury, Monash University, 11 May 2017
  • WO/2017/075653, Chlamydia antigens and uses thereof, University of the Sunshine Coast, 11 May 2017
  • WO/2017/070752, Imaging agents, University of Queensland, 4 May 2017
  • WO/2017/070744, Methods and compositions for improving glucose metabolism, Monash University, 4 May 2017
  • WO/2017/070738, A method of treatment and agents useful for same, University of Queensland and QIMR Berghofer Medical Research Institute, 4 May 2017
  • WO/2017/070735, Liposomal vaccine, Griffith University, 4 May 2017
  • WO/2017/070731, Compositions and methods for the treatment of Alzheimer's disease, Innate Immunotherapeutics Ltd, 4 May 2017
  • WO/2017/066827, Methods of reducing mammographic breast density and/or breast cancer risk, Havah Therapeutics Pty Ltd, 27 April 2017
  • WO/2017/063023, Compositions and methods for the treatment of diseases involving mucin, University of New South Wales, 20 April 2017
  • WO/2017/063017, Treatment or prevention of giardiasis with a biologically active extract from Terminalia ferdinandiana fruit, Gunaguddya Pty Ltd, 20 April 2017
  • WO/2017/059486, Compositions and methods for the treatment of epilepsy, Innate Immunotherapeutics Ltd, 13 April 2017
  • WO/2017/059485, Compositions and methods for protection and/or repair of the nervous system, Innate Immunotherapeutics Ltd, 13 April 2017
  • WO/2017/059319, Combination therapy of bromodomain inhibitors and checkpoint blockade, Dana-Farber Cancer Institute (US) and Peter MacCallum Cancer Institute, 6 April 2017
  • WO/2017/054047, Antimicrobial polymyxin derivative compounds, Monash University, 6 April 2017
  • WO/2017/054042, Novel formulation and treatment methods, University of Queensland, 6 April 2017
  • WO/2017/049349, A method of treatment and prophylaxis, Hudson Institute of Medical Research, 30 March 2017
  • WO/2017/045034, Ubiquinone and ubiquinol compositions, and methods relating thereto, Pharmako Biotechnologies Pty Ltd, 23 March 2017
  • WO/2017/045019, Antibiotic therapy, Boulos & Cooper Pharmaceuticals Pty Ltd, 23 March 2017
  • WO/2017/041142, Polymer conjugate comprising a bioactive agent, Polyactiva Pty Ltd, 16 March 2017
  • WO/2017/041139, Lymph directing prodrugs, Monash University, 16 March 2017
  • WO/2017/041133, Cell expansion methods and therapeutic compositions, Cell Ideas Pty Ltd, 16 March 2017
  • WO/2017/035595, Formation of bone, Elastagen Pty Ltd,  9 March 2017
  • WO/2017/035587, Bioactive polymer for bone regeneration, University of Sydney, 9 March 2017
  • WO/2017/035582, Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins, University of Adelaide, 9 March 2017
  • WO/2017/035566, Plasma polymerised oxazoline coatings and uses thereof, University of South Australia, 9 March 2017
  • WO/2017/031299, Enzymatic fractions with anti-inflammatory activity, Anatara Lifesciences Ltd, 23 February 2017
  • WO/2017/030901, Mycoplasma bovis compositions, Zoetis (US) and University of Melbourne, 23 February 2017
  • WO/2017/027910, Connexin 45 inhibition for therapy, University of Sydney and Western Sydney Local Health District, 23 February 2017
  • WO/2017/027898, Novel cancer treatment involving modulation of Il-3 activity, University of South Australia and Central Adelaide Local Health Network, 23 February 2017
  • WO/2017/025635, Composition for the treatment of joint conditions, Newven SPRL (Ransart, Belgium) and four inventors including Simon Humphrys of Adelaide, 16 February 2017
  • WO/2017/024355, Compositions comprising S1P receptor modulators, Akaal Pharma Pty Ltd, 16 February 2017
  • WO/2017/020094, Methods for treating tumours, Centenary Institute of Cancer Medicine and Cell Biology, Mirrx Therapeutics A/S and University of Sydney, 9 February 2017
  • WO/2017/020087, Emollient composition, Eupharma Pty Ltd, 9 February 2017
  • WO/2017/020086, Benzodiazepines as bromodomain inhibitors, Catalyst Therapeutics Pty Ltd, 9 February 2017
  • WO/2017/020065, n-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds, University of South Australia, 9 February 2017
  • WO/2017/017511, Modified release formulation for treating premature ejaculation, Selim Kameel, 2 February 2017
  • WO/2017/015722, Complexes for intracellular imaging, University of South Australia and Curtin University of Technology, 2 February 2017
  • WO/2017/015720, Fibrotic treatment, Monash University, 2 February 2017
  • WO/2017/015703, Antiseptic polymer and synthesis thereof, University of Sydney, 2 February 2017
  • WO/2017/011863, Neuroprotective agents derived from spider venom peptides, University of Queensland and Monash University, 26 January 2017
  • WO/2017/008101, Novel aminopeptidase inhibitors and methods of use, Monash University, 19 January 2017
  • WO/2017/004678, Cross-reactive antifungal adoptive T cell therapy, University of Sydney and Western Sydney Local Health District, 12 January 2017
  • WO/2017/004674, Therapeutic compounds and compositions for treating social disorders and substance use disorders, University of Sydney, 12 January 2017
  • WO/2017/004672, Peptidyl TPOR antagonists and uses thereof, Polymers CRC Ltd, 12 January 2017

New Zealand applications

Here are the 24 PCT patent applications relevant to New Zealand's Life Sciences sector that published in 2017, for a publication rate of 0.5 applications per week:​
  • WO/2017/217868, Water-dispersible propolis composition, Andrew Lavrent, 21 December 2017
  • WO/2017/213524, Treatment of neurodegenerative disorders, Garth Cooper, 14 December 2017
  • WO/2017/200396, Antibacterial compositions, David Ackerley and Janine Copp, 23 November 2017
  • WO/2017/200391, Compositions comprising L-Theanine, proanthocyanidin/s and a catechin and uses thereof, Alphagen NZ, 23 November 2017
  • WO/2017/192620, Novel peptides and peptidomimetics, University of Auckland and Ocunexus Therapeutics, 9 November 2017
  • WO/2017/183996, Combination,therapeutic uses and prophylactic uses, Quantec Ltd, 26 October 2017
  • WO/2017/179996, Collagen-based device having antifungal properties, Aroa Biosurgery, 19 October 2017
  • WO/2017/171563, Beta-caseins and cognitive function, A2 Milk Company, 5 October 2017
  • WO/2017/164750, Therapeutic compositions and uses thereof, Manuka Health New Zealand Ltd, 28 September 2017
  • WO/2017/153943, Topical composition, Biopharm NZ Ltd, 14 September 2017
  • WO/2017/142424, Treatment of neurodegenerative disorders, Garth Cooper, 24 August 2017
  • WO/2017/131534, Treatment of vascular anomalies, Gillies McIndoe Research Institute, 3 August 2017
  • WO/2017/111618, Infant formula comprising human milk peptides, A2 Milk Company Ltd, 29 June 2017
  • WO/2017/099612, Marker compounds of Leptospermum honeys and methods of isolation and assaying thereof, Comvita Ltd, 15 June 2017
  • WO/2017/095237, Carbon monoxide releasing norbornenone compounds, Ivan Sammut et. al., 8 June 2017
  • WO/2017/082753, Glycolipid compounds and their uses in the treatment of tumours, Agalimmune Ltd (UK) with Kode Biotech, 18 May 2017
  • WO/2017/078544, Nutrient loss reduction method, PGG Wrightson Seeds Ltd, 11 May 2017
  • WO/2017/074262, Core-shell composite material, Agency for Science, Technology and Research (Singapore) with Massey University and AgResearch, 4 May 2017
  • WO/2017/065619, Nitrogen utilisation modulation, PGG Wrightson Seeds Ltd, 20 April 2017
  • WO/2017/061878, Antimicrobial gel containing silver nanoparticles, Carla Meledandri, 13 April 2017
  • WO/2017/034420, Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) and their use in therapy, Auckland Uniservices Ltd, 2 March 2017
  • WO/2017/034418, Acoustic driven drug delivery systems, John Reynolds, 2 March 2017
  • WO/2017/018889, Manuka and/or kanuka honey wet wipes and manuka and/or kanuka oil tissues, Imbue NZ Ltd, 2 February 2017
  • WO/2017/003305, Peptides and uses thereof, Auckland Uniservices Ltd, 5 January 2017

Copyright © 2017 NDF Research
Proudly powered by Weebly
  • Introducing NDF
  • About us
    • About our Senior Analyst
    • Disclaimer relating to research and web content
    • Financial Services Guide and General Advice Warning
  • What we do
    • The Rise of the New Analysts
    • MiFID II
  • Our sector
    • ASX-Listed Life Science companies we watch >
      • ASX-listed Life Science companies, >$200m
      • ASX-listed Life Science companies, $100-200m
    • About Australia and Australians
    • Australia and the Life Sciences
    • Life Sciences in New Zealand >
      • Building the New Zealand Life Sciences sector
    • A tour of Life Sciences Down Under
    • Australia's global competitiveness in Life Sciences >
      • Australia's Life Sciences Innovation Rating
      • Australia's Life Sciences clusters
      • Australia's World-Class Universities
      • Australia's Nobel Laureates
      • Australia's public policy support for Life Sciences
      • Australia's support for women in Life Sciences
    • The Coming Boom in Australian Life Sciences >
      • Welcome to Australia's Life Sciences Boom
    • Key organisations in the Life Science sector in Australia and New Zealand
    • Notable people in the Life Sciences sector in Australia and New Zealand >
      • Great CEOs
      • 2017 Red Hat Award Winners
      • 2018 Red Hat Award Winners
      • 2019 Red Hat Award Winners
    • The NDF Life Sciences Index >
      • 2016-2017 Year in Review
  • Our clients
  • Contact us
    • linkedin
    • Twitter
    • NDF Research Youtube Channel
  • Latest research
    • Comprehensive update reports
    • Shorter update reports
    • Initiation reports >
      • Admedus
      • Invion
    • Media and interviews
    • Presentations
    • Previous research and media, 2003-2015
    • A Brief History of the Life Sciences in Australia
    • In our library
    • Intellectual property >
      • Australian PCT patent applications
      • New Zealand PCT patent applications
      • PCT patent applications, last twelve months >
        • 2017 PCT patent applications
        • 2016 PCT patent applications
        • 2015 PCT patent applications
        • 2014 PCT patent applications
        • 2013 PCT patent applications
      • US patents >
        • 2017 US patents
        • 2016 US patents
        • 2015 US patents
        • 2014 US patents
    • Publications
    • Glossary
    • Global Life Science companies to watch
  • Blog